{"id":15504,"date":"2024-11-28T18:04:23","date_gmt":"2024-11-28T10:04:23","guid":{"rendered":"https:\/\/flcube.com\/?p=15504"},"modified":"2024-11-28T18:04:26","modified_gmt":"2024-11-28T10:04:26","slug":"allink-biotherapeutics-secures-42-million-in-series-a-financing-to-advance-bispecific-antibodies-and-adcs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15504","title":{"rendered":"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs"},"content":{"rendered":"\n<p>Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), has reportedly raised $42 million via a Series A financing round. The funding round was led by Lanchi Ventures, with additional contributions from YuanBio Venture Capital, Legend Capital, and Xiamen C&amp;D Emerging Industry Equity Investment, along with returning investors Gaorong Capital and Med-Fine Capital.<\/p>\n\n\n\n<p><strong>Funding Allocation and Pipeline Advancement<\/strong><br>The proceeds from the financing will be utilized to accelerate Allink Biotherapeutics&#8217; global layout, including the advancement of Phase I clinical studies for its core pipelines, ALK201 and ALK202, in Australia, the United States, and China. The company plans to expand its cancer and immune disease pipelines and optimize its in-house BsAb and ADC technology platforms.<\/p>\n\n\n\n<p><strong>Expanding Pipeline and Technology Platforms<\/strong><br>By investing in the development of its BsAb and ADC technology platforms, Allink Biotherapeutics aims to strengthen its position in the biotech industry and enhance its capabilities to bring innovative treatments to market. The expansion of its cancer and immune disease pipelines reflects the company&#8217;s commitment to addressing unmet medical needs and improving patient outcomes.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":15508,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,2446,20,28],"class_list":["post-15504","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-allink-biotherapeutics","tag-finance","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), has reportedly raised $42 million via a Series A financing round. The funding round was led by Lanchi Ventures, with additional contributions from YuanBio Venture Capital, Legend Capital, and Xiamen C&amp;D Emerging Industry Equity Investment, along with returning investors Gaorong Capital and Med-Fine Capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15504\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15504\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-28T10:04:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-28T10:04:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/2877.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"713\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs\",\"datePublished\":\"2024-11-28T10:04:23+00:00\",\"dateModified\":\"2024-11-28T10:04:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504\"},\"wordCount\":205,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/2877.png\",\"keywords\":[\"ADC \\\/ XDC\",\"Allink Biotherapeutics\",\"Finance\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15504#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15504\",\"name\":\"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/2877.png\",\"datePublished\":\"2024-11-28T10:04:23+00:00\",\"dateModified\":\"2024-11-28T10:04:26+00:00\",\"description\":\"Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), has reportedly raised $42 million via a Series A financing round. The funding round was led by Lanchi Ventures, with additional contributions from YuanBio Venture Capital, Legend Capital, and Xiamen C&D Emerging Industry Equity Investment, along with returning investors Gaorong Capital and Med-Fine Capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15504\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/2877.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/2877.png\",\"width\":1080,\"height\":713,\"caption\":\"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15504#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), has reportedly raised $42 million via a Series A financing round. The funding round was led by Lanchi Ventures, with additional contributions from YuanBio Venture Capital, Legend Capital, and Xiamen C&D Emerging Industry Equity Investment, along with returning investors Gaorong Capital and Med-Fine Capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15504","og_locale":"en_US","og_type":"article","og_title":"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15504","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-28T10:04:23+00:00","article_modified_time":"2024-11-28T10:04:26+00:00","og_image":[{"width":1080,"height":713,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/2877.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15504#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15504"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs","datePublished":"2024-11-28T10:04:23+00:00","dateModified":"2024-11-28T10:04:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15504"},"wordCount":205,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=15504#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/2877.png","keywords":["ADC \/ XDC","Allink Biotherapeutics","Finance","Multi-specific antibodies"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15504#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15504","url":"https:\/\/flcube.com\/?p=15504","name":"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=15504#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=15504#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/2877.png","datePublished":"2024-11-28T10:04:23+00:00","dateModified":"2024-11-28T10:04:26+00:00","description":"Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), has reportedly raised $42 million via a Series A financing round. The funding round was led by Lanchi Ventures, with additional contributions from YuanBio Venture Capital, Legend Capital, and Xiamen C&D Emerging Industry Equity Investment, along with returning investors Gaorong Capital and Med-Fine Capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15504#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15504"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=15504#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/2877.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/2877.png","width":1080,"height":713,"caption":"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15504#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/2877.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15504"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15504\/revisions"}],"predecessor-version":[{"id":15509,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15504\/revisions\/15509"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/15508"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}